Latest MD Buyline Report Shows Highest User Satisfaction Composite Ratings for Accuray Incorporated

PR57381

SUNNYVALE, Calif., July 17, 2014 /PRN-KYODO JBN/ --

Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife(R) [

http://www.accuray.com/solutions/treatment-delivery/cyberknife-treatment-delivery/m6-series

] and TomoTherapy(R)[

http://www.accuray.com/solutions/treatment-delivery/tomotherapy-treatment-delivery/h-series

] Systems have received the highest composite overall user satisfaction rating

among radiation treatment delivery systems in the U.S., according to the Q2

2014 MD Buyline Market Intelligence Briefing(TM). The latest ratings show

continuously improving customer satisfaction during the past one-and-a-half

years as Accuray demonstrated significant and sustained improvements.

In rating Accuray, MD Buyline* reports higher scores for system performance,

system reliability, service response time and applications training for both

the CyberKnife and TomoTherapy Systems, validating the company's focus on

service excellence and technology performance. TomoTherapy System users believe

that the system is a workhorse, with the report indicating that they "love this

system and believe that it is one of the best systems on the market for

radiation oncology treatments." CyberKnife System users also conveyed positive

experiences, stating that they are "pleased with the level of flexibility the

system allows" and that it is a "solid and durable system."

"The composite MD Buyline rating for both our company and our product platforms

confirms and validates the efforts we have made to deliver a best-in-class

customer experience," said Joshua H. Levine, president and CEO of Accuray. "Our

customers require the most precise, effective and efficient radiation therapy

products and we are committed to providing exactly that."

MD Buyline, an independent market intelligence organization for the healthcare

industry, measures linear accelerator user satisfaction based on evaluations by

more than 3,300 hospitals in its member network that use the product every day.

Respondents rate how satisfied they are with products from Accuray, Elekta and

Varian, using key metrics listed above along with installation and

implementation, applications training, and service repair quality. (MD Buyline

User Satisfaction Ratings, MD Buyline Market Intelligence Briefing(TM) Q2 2014)

(C) 2014 MD Buyline, All Rights Reserved. Used with Permission 7/10/14.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that

develops, manufactures and sells precise, innovative tumor treatment solutions

that set the standard of care with the aim of helping patients live longer,

better lives. The company's leading-edge technologies deliver the full range of

radiation therapy and radiosurgery treatments. For more information, please

visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical

fact are forward-looking statements and are subject to the "safe harbor"

provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements in this press release relate, but are not limited to

clinical performance, clinical results, future market success and trends,

customer satisfaction and adoption of the company's products or services, and

the company's leadership position in radiation oncology innovation and

technologies. Forward-looking statements are subject to risks and uncertainties

that could cause actual results to differ materially from expectations,

including but not limited to the risks detailed from under the heading "Risk

Factors" in the company's report on Form 10-K, which was filed on August 29,

2013, the company's report on Form 10-Q, which was filed on May 7, 2014, and as

updated periodically by the company's other filings.

Forward-looking statements speak only as of the date the statements are made

and are based on information available to the company at the time those

statements are made and/or management's good faith belief as of that time with

respect to future events. Accuray assumes no obligation to update

forward-looking statements to reflect actual performance or results, changes in

assumptions or changes in other factors affecting forward-looking information,

except to the extent required by applicable securities laws. Accordingly,

investors should not put undue reliance on any forward-looking statements.

SOURCE: Accuray Incorporated

CONTACT: Beth Kaplan, Accuray, +1 (408) 789-4226, bkaplan@accuray.com, OR

Kirsten Fallon, MSLGROUP in Boston, +1 (781) 684-0770,

Kirsten.Fallon@MSLGROUP.com